On 5 Nov 2026, our scan flagged GILD as a rounding bottom setup scoring 76 out of 98 (Good tier), with a 74% win probability based on our historical pattern database and a 0.92 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $174.48, the conservative target is $183.27 with a stop at $164.88.
Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.
Current Setup
GILD has formed a rounding bottom pattern following recent strength driven by third-quarter results announcing product sales growth of 16% year-over-year excluding Veklury. The stock sits at $174.48, up 52.64% from its 52-week low, forming the right side of the recovery. Structure score of 15/15 indicates well-defined support and resistance levels at $119.92 and $148.45 respectively. Volume ratio of 1.41x confirms above-average accumulation (9.5M shares vs. 6.8M average). Breakout score of 10/13 suggests gradual momentum building; the 73-day RSI reading of 73.3 signals overbought conditions that could precede either breakout confirmation or pullback, warranting caution on immediate trend continuation.
Stock Context
Gilead delivered exceptional third-quarter results with strongest year-over-year base business growth in over a decade, with management raising full-year base business revenue guidance by a total of $1.6 billion since start of 2026. HIV business grew 18% with prevention sales nearly doubling, and the company has multiple ongoing launches across HIV and Oncology with important progress in Inflammation. On November 4, 2026, Gilead announced 23 presentations at the American Society of Hematology annual meeting including seven oral presentations on therapeutic pipeline advancements. On November 2, 2026, Gilead maintained its quarterly dividend at $0.82 per share. The rounding bottom forms amid operational momentum—strong earnings, pipeline advancement, and strategic clarity are attracting capital into the name.
What to Expect
A successful breakout above the $148.45 resistance would target $183.27 conservatively—a 23.5% measured move. Volume confirmation would require sustained relative volume above 1.2x to validate breakout integrity given current elevated volatility (33.34% 20-day realized). Win probability of 73.68% historically favors mean reversion completion. Invalidation occurs below $119.92 support; breach below that level would negate the rounding bottom thesis and suggest continuation of prior downtrend. Breakout timing remains uncertain; overbought RSI (73.3) may require a brief consolidation before upside acceleration.
Risk Factors
Insider activity signals caution: over the past 12 months, insiders have sold $92 million worth of shares with no insider purchases reported. RSI of 73.3 indicates overbought conditions, increasing pullback risk in near term. High beta of -0.18 and elevated volatility (33.34%) mean GILD may underperform during market rallies, contradicting typical bullish setup assumptions. Health Care sector is bullish (0.83 regime score), but broader market is bearish (-0.31), creating cross-current headwinds. Stock has already appreciated 35% over three months and 9.6% in one week—extended gain may face profit-taking. Next key catalyst is Q4 2026 earnings (likely January/February 2027), leaving pattern subject to interim volatility without near-term data inflection points to sustain momentum.
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is GILD a good swing trade?
GILD scored 76 out of 98 on our rounding bottom scan, with a 74% historical win probability over a 2-8 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $174.48, with a conservative target of $183.27 and a stop loss at $164.88.
What would invalidate this rounding bottom setup?
A close below the stop loss at $164.88 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical rounding bottom setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish-0.31
-1.00+1.0
Health Care Sector
Bullish0.83
-1.00+1.0
Overall Score
37of 40
Exceptional
Pattern Quality
16of 20
Strong
Setup
13of 20
Moderate
R/R
10of 18
Fair
Context
Pattern Quality Score
15of 15
Exceptional
Structure
10of 13
Good
Breakout
12of 12
Exceptional
Volume
Recent Performance
+9.6%
1W
+13.6%
2W
+21.0%
1M
+34.1%
3M
Momentum & Trend
RSI (14)
73.3
Overbought
MACD Histogram
+1.40
Strong Bullish
Bollinger Band Position
102.5%
Upper Band
Volatility & Risk
20-Day Volatility
0.33
Moderate
ATR %
2.8%
Medium
Beta
-0.18
Defensive
Volume Analysis
Volume Ratio
1.41x
Above Avg
20-Day Avg Vol
6.8M
shares / day
Current Volume
9.5M
shares traded
Price Levels
Target
$183.27
52W High
$175.66
Current
$174.48
Stop Loss
$164.88
Resistance
$148.45
Support
$119.92
52W Low
$114.31
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.